Board Appointments
21 August 2026
genedrive plc
("genedrive" or the "Company")
Board Appointments
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr Mark Winkler and Mr Mike Fairbourn have agreed to join the Board as independent Non-Executive Directors with effect from 1 September 2026.
The appointments strengthen the Board's financial, strategic, healthcare and commercial expertise as genedrive enters its next phase of growth, focused on scaling adoption of its pharmacogenetic tests in the UK and expanding its international business.
Mark brings extensive financial, strategic and corporate finance experience, advising growth companies, multinational businesses and investors on strategy, finance, governance and growth capital. He is the founder and CEO of Red Earth Advisors and previously held senior roles at Stonehage Fleming and Deloitte where he qualified as an ACA.
Mike brings more than three decades of commercial and leadership experience across the pharmaceutical and medical technology sectors. He spent almost 20 years at global medical technology company Becton Dickinson, including as Vice President and General Manager for the UK and Ireland, and served for ten years on the Board of the Association of British HealthTech Industries ("ABHI"), the UK's leading industry association for health technology, including products such as single use devices, diagnostics and digitally enhanced technologies.
It is proposed that Mark Winkler will chair the Company's Audit and Remuneration Committees.
As previously communicated, Chris Yates, who has served on the Board since 2018, has today stepped down as a Non-Executive Director in order to focus on his other professional commitments.
Mr Graham Cole CBE, Chairman of genedrive plc, said: "Mark and Mike bring highly complementary experience and skills to the Board at an important stage for genedrive as we build on the progress already made and look to further scale the business. Their experience will be invaluable as we focus on broadening adoption of our pharmacogenetic tests, strengthening commercial execution and delivering sustainable growth and value for shareholders.
"On behalf of the Board, I would like to thank Chris for his commitment and significant contribution to genedrive over the past eight years, and for his support during this period of Board transition. We wish him continued success in the future."
Mr Mark Winkler, Non-Executive Director of genedrive plc, said: "genedrive has built a strong foundation and I look forward to working with Graham, Gino and the wider Board, bringing my financial, strategic and governance experience to support disciplined growth and the Company's ambitions as it scales."
Mr Mike Fairbourn, Non-Executive Director of genedrive plc, said: "genedrive has developed innovative pharmacogenetic tests addressing important clinical needs. Having spent much of my career working at the interface between healthcare innovation and clinical practice, I am particularly excited by the opportunity to help broaden adoption and embed these technologies into healthcare pathways in the UK and internationally."
Additional Information on Mark Winkler
The following additional information is provided with regard to the appointment of Mark Alan Winkler, aged 49, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:
|
|
|
|
Current relevant directorships/partnerships: |
Former relevant directorships/partnerships (within the last five years): |
|
Concise Media Consulting Limited |
Liquidity Media Midco Limited |
|
Liquidity Media Limited |
|
|
Red Earth Advisors Limited |
|
|
4 Sumatra Road Limited |
|
Mark Winkler does not hold any ordinary shares in the Company.
There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Additional Information on Mike Fairbourn
The following additional information is provided with regard to the appointment of Michael John Fairbourn, aged 67, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:
|
|
|
|
Current relevant directorships/partnerships: |
Former relevant directorships/partnerships (within the last five years): |
|
Deko MedTech Oy |
Association of British Healthtech Industries Limited |
|
Fairbourn Consulting Limited |
Becton Dickinson Holdings Designated Activity Company |
|
|
Becton, Dickinson U.K. Limited |
Mike Fairbourn does not hold any ordinary shares in the Company.
There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
|
genedrive plc |
+44 (0)161 989 0245
|
|
Gino Miele: CEO / Russ Shaw: CFO |
https://investors.genedrive.com/s/e0025c
|
|
|
|
|
Peel Hunt LLP (Nominated Adviser and Broker) |
+44 (0)20 7418 8900 |
|
James Steel |
|
|
|
|
|
5654 & Company (Media & Investor Relations) |
genedrive@5654.co.uk |
|
Matthew Neal |
+44 (0)7917 800 011 |
|
Melissa Gardiner |
+44 (0)7757 697357 |
Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
About genedrive plc (http://www.genedrive.com).
genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.
genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention
The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.
Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE